# ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

> **NCT01001377** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 1010 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01001377
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-02
- **Primary completion:** 2013-02-05
- **Final completion:** 2017-03-07
- **Target enrollment:** 1010 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001377, "ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01001377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*